Profil
Da Qing Cai served as a Director at Bionano Genomics, Inc. from 2018 to 2019.
Prior to that, he was a Director at Berry Genomics Co., Ltd.
from 2017 to 2018.
He also held the position of Independent Non-Executive Director at Jacobio Pharmaceuticals Group Co., Ltd.
from 2020 to 2023.
Additionally, Dr. Cai worked as a Director at Beijing Shenogen Pharma Group Ltd.
from 2016 to 2019.
He obtained a graduate degree from Yale University in 1998, a doctorate degree from the University of California, Berkeley in 1996, and an undergraduate degree from the University of Science & Technology of China in 1989.
Anciens postes connus de Da Qing Cai
| Sociétés | Poste | Fin |
|---|---|---|
| JACOBIO PHARMACEUTICALS GROUP CO., LTD. | Directeur/Membre du Conseil | 23/03/2023 |
| BIONANO GENOMICS, INC. | Directeur/Membre du Conseil | 01/08/2019 |
Beijing Shenogen Pharma Group Ltd.
 Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China. | Directeur/Membre du Conseil | 01/03/2019 |
| BERRY GENOMICS CO.,LTD | Directeur/Membre du Conseil | 01/04/2018 |
Formation de Da Qing Cai
| University of Science & Technology of China | Undergraduate Degree |
| Yale University | Graduate Degree |
| University of California, Berkeley | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| BERRY GENOMICS CO.,LTD | Health Technology |
| JACOBIO PHARMACEUTICALS GROUP CO., LTD. | Health Technology |
| BIONANO GENOMICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Beijing Shenogen Pharma Group Ltd.
Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China. | Health Technology |
